ISRCTN43525354已完成不适用
Anti-CD20 therapy for the treatment of chronic Graft Versus Host Disease
niversity Medical Center Utrecht (UMCU) (The Netherlands)0 个研究点目标入组 30 人开始时间: 2006年10月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged over 18 years
- •2. Steroid refractory chronic GVHD, including skin localisation
- •3. No other treatment apart from steroids and when applicable standard GVHD prevention
排除标准
- •1. Relapse with a life expectancy of less than six months
- •2. Severe infections
研究者
相似试验
尚未招募
不适用
Anti-CD20 therapy for the treatment ofchronic graft versus host disease.30 patients with a steroid refractory cGVHD will be treated with anti-B-cell therapyNL-OMON27646Roche Nederland B.V.30
已完成
不适用
ANTI-CD20 THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASEchronic graft-versus-host disease, allogeneic stem cell transplantation, B-cell depletionNL-OMON27822niversity Medical Centre UtrechtP.O. Box 855003508 GA Utrecht, The Netherlands30
已完成
不适用
Anti-CD20 treatment of relapsed or refractory immune thrombocytopaenic purpura (ITP) after first line corticosteroid treatmentImmune thrombocytopaenic purpura (ITP)Haematological DisordersPurpura and other haemorrhagic conditionsISRCTN16619820Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands) - Data Centre150
已完成
不适用
Anti-CD20 monoclonal antibody therapy for type II mixed cryoglobulinemia syndromeMixed cryoglobulinemia HCV- related or unrelatedHaematological DisordersCryoglobulinaemiaISRCTN55287110niversity of Udine (Italy)124
已完成
2 期
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell LymphomaDiffuse large B-cell lymphomaC83.3C82.4C85.1Follicular lymphoma grade IIIbB-cell lymphoma, unspecifiedDRKS00009416niversitätsmedizin der Johannes Gutenberg-Universität Mainz70